

Tumor Types Enrolling

- Melanomas

Inclusion Criteria

- Must have a confirmed active melanoma tumor diagnosis
- Must have a tumor amenable to receive injection (IT chemo) and/or ultrasound imaging (HIFU)

Exclusion Criteria

- Severe chronic diseases (e.g. some cardiovascular diseases, history of anesthetic complications) that increase the risk for anesthetic or treatment complications
- Prior chemotherapy treatments

Procedures

- Questionnaire before consultation, and questionnaires during treatment (every 3 weeks) and at each post-treatment visit (at least at 3, 6, and 12 weeks)
- Physical exams at consultation, treatment, and post-treatment visits
- Sample collection (e.g. blood, urine, feces, etc.) and possible imaging (MRI, CT, X-ray, ultrasound, etc.) at consultation, treatment, and post-treatment visits. A CT or ultrasound will be taken at 6-week post-treatment visit.
- Patients will be evaluated at 2 months post-treatment to determine if additional therapies need to be pursued and if extended monitoring is needed.

**Clinicians may decide that your pet is in need of additional samples/diagnostics at any time throughout the study based on their current health condition. Post-treatment follow-up visits for 3 months are mandatory for on-study pets.*

Study #4

Veterinary Clinical Trials in Canine and Feline Patients Using Combination Novel Therapeutics, Devices, and Data Collection Techniques

Study objective: To assess the safety, tumor response, and delivery efficiency of carboplatin chemotherapy administered intratumorally (IT) (into the tumor) versus intravenously (IV) (into the veins), with or without high-intensity focused ultrasound (HIFU) enhancement, in dogs with naturally occurring melanoma. Carboplatin administered alone has limited efficacy and can cause systemic toxicity in canines with melanoma. This study aims to evaluate whether combining carboplatin with HIFU hyperthermia enhances intratumoral drug delivery, overcomes chemoresistance, and promotes the release of tumor antigens to enhance the antitumor immune response via IT and IV routes.

Treatments

Arm 1

- Carboplatin: given IV every 3 weeks for 3-4 cycles (9-12 weeks)
- Without HIFU (hyperthermia): given concurrently with chemotherapy for 9-12 weeks

Arm 2

- Carboplatin: given IV every 3 weeks for 3-4 cycles (9-12 weeks)
- With HIFU (hyperthermia): given concurrently with chemotherapy for 9-12 weeks

Arm 3

- Carboplatin: given IT every 3 weeks for 3-4 cycles (9-12 weeks)
- Without HIFU (hyperthermia): given concurrently with chemotherapy for 9-12 weeks

Arm 4

- Carboplatin: given IT every 3 weeks for 3-4 cycles (9-12 weeks)
- With HIFU (hyperthermia): given concurrently with chemotherapy for 9-12 weeks

Treatment Timeline

